hanxiang An

Prof. hanxiang An


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in The American Journal of Pathology
Verified
Journal Article
Closed access
HAhanxiang An
hanxiang An
MBMatthias W. Beckmann
Matthias W. Beckmann
GRGuido Reifenberger
Guido Reifenberger
HBHans G. Bender
Hans G. Bender
DNDieter Niederacher
Dieter Niederacher

5 September 2007 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
EFEmmanouil Fokas
Emmanouil Fokas
RERita Engenhart-Cabillic
Rita Engenhart-Cabillic
KDKiriakos Daniilidis
Kiriakos Daniilidis
FRFrank Rose
Frank Rose
HAhanxiang An
hanxiang An

1 July 1996 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
PDF file
JRJulia Reifenberger
Julia Reifenberger
GRGudrun U. Ring
Gudrun U. Ring
UGUrsula Gies
Ursula Gies
JCJ. M.J. Ludwig Cobbers
J. M.J. Ludwig Cobbers
JOJorgen Oberstrab
Jorgen Oberstrab
JOJürgen Oberstraß
Jürgen Oberstraß
Genomic alterations and expression of the p53 tumor suppressor gene and the epidermal growth factor receptor gene (EGFR) were investigated in 22 patients with primary World Health Organization (WHO) grade II gliomas that on recurrence had progressed to malignant gliomas of WHO grades III or IV. Mutations of the p53 gene (exons 5 to 8) were found in 12 of 22 primary tumors (10 of 13 astrocytomas, 1 of 7 oligodendrogliomas, 1 of 2 oligoastrocytomas). In each of these cases identical p53 mutations were present in the respective malignant recurrences. In all instances in which the p53 mutation was associated with p53 protein accumulation (10 of 12 cases) the percentage of p53 immunopositive tumor cells had increased from the primary to the recurrent tumor. None of the primary low-grade and none of the recurrent high-grade tumors (7 anaplastic astrocytomas, 10 anaplastic oligodendrogliomas, 4 anaplastic oligoastrocytomas, and 5 glioblastomas) showed evidence of EGFR gene amplification. Our results thus demonstrate that p53 is mutated in a high fraction of low-grade astrocytomas with progression to anaplastic astrocytomas and glioblastomas and that progression in such cases is frequently associated with an increase in the fraction of p53 immunopositive tumor cells. The general absence of EGFR amplification in our tumor series supports the hypothesis that the significance of p53 mutation and EGFR amplification may be different in glioblastomas that developed by progression from low-grade astrocytomas (secondary glioblastomas) compared to glioblastomas that developed rapidly in a de novo manner without a history of previous low-grade tumor (primary glioblastomas).

1 March 2015
Verified
Journal Article
Open access
PDF file
ZPZhen-Kui Pan
Zhen-Kui Pan
FYFeng Ye
Feng Ye
XWXuan Wu
Xuan Wu
HAhanxiang An
hanxiang An
JWJing-Xun Wu
Jing-Xun Wu
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis

21 December 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PXPeng Xia
Peng Xia
HAhanxiang An
hanxiang An
CDCheng-Xue Dang
Cheng-Xue Dang
RRRamin Ramin Radpour
Ramin Ramin Radpour
CKCorina Kohler
Corina Kohler
XZXiao Yan Zhong
Xiao Yan Zhong
Background: Alterations of mitochondrial DNA (mtDNA) have been implicated in carcinogenesis. We developed an accurate multiplex quantitative real-time PCR for synchronized determination of mtDNA and nuclear DNA (nDNA). We sought to investigate whether mtDNA content in the peripheral blood of breast cancer patients is associated with clinical and pathological parameters. Methods: Peripheral blood samples were collected from 60 patients with breast cancer and 51 age-matched healthy individuals as control. DNA was extracted from peripheral blood for the quantification of mtDNA and nDNA, using a one-step multiplex real-time PCR. A FAM labeled MGB probe and primers were used to amplify the mtDNA sequence of the ATP 8 gene, and a VIC labeled MGB probe and primers were employed to amplify the glyceraldehyde-3-phosphate-dehydrogenase gene. mtDNA content was correlated with tumor stage, menstruation status, and age of patients as well as lymph node status and the expression of estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu protein. Results: The content of mtDNA in stage I breast cancer patients was significantly lower than in other stages (overall P = 0.023). Reduced mtDNA was found often in post menopausal cancer group (P = 0.024). No difference in mtDNA content, in regards to age (p = 0.564), lymph node involvement (p = 0.673), ER (p = 0.877), PR (p = 0.763), and Her-2/neu expression (p = 0.335), was observed. Conclusion: Early detection of breast cancer has proved difficult and current detection methods are inadequate. In the present study, decreased mtDNA content in the peripheral blood of patients with breast cancer was strongly associated with stage I. The use of mtDNA may have diagnostic value and further studies are required to validate it as a potential biomarker for early detection of breast cancer.

5 April 1998 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
JCJ.M.J. Ludwig Cobbers
J.M.J. Ludwig Cobbers
MWMarietta Wolter
Marietta Wolter
JRJulia Reifenberger
Julia Reifenberger
GRGudrun U. Ring
Gudrun U. Ring
FJFrank Jessen
Frank Jessen
GRGuido Reifenberger
Guido Reifenberger